AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

TOKYO & BASKING RIDGE, N.J., April 21, 2025--ENHERTU Combination Demonstrated Statistically Significant Improvement in PFS vs. THP as First-Line Therapy in HER2 Positive Metastatic Breast Cancer ...

Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically ...